Adobe reported record revenue of $6.62 billion in its fiscal Q2, raised its full-year guidance, and beat on every line item. The stock hit a 7-year low that same week.
Chewy beat on earnings per share and grew revenue 7.7% - then cut its full-year sales outlook and fell to a fresh 52-week low of $19.08. Boston Scientific topped Q1 revenue estimates while simultaneously slashing its organic growth guidance to 6.5–8%, sending the stock to $45.99 - nearly 57% off its 52-week high.
Three different companies, three different industries, one shared outcome: backward results don't matter anymore when the market has already decided what the next year looks like. But that's not the full story. Beneath the common denominator of guidance disappointment sits a much sharper divide - and only one of these three companies is sitting directly in the crosshairs of a structural market transition.
Let's start where it matters most for anyone tracking the AI cycle. Adobe delivered what should have been a textbook confirmation of the AI-creative-software thesis. Subscription revenue for Creative & Marketing Professionals hit $4.54 billion, up 11% year over year. The company raised its FY26 revenue outlook to $26.5–26.6 billion. Firefly - Adobe's generative AI creative engine - is generating real demand for AI content creation across enterprise customers.
Adobe: The AI story is becoming an AI problem
The stock still fell to around $223 before digging deeper. Then it hit $196.90 - an 8-year low, down roughly 50% from its June 2025 peak of $405.
Here's what actually moved the stock. On the same day as the earnings report, Adobe announced that CFO Dan Durn is departing to join Marvell Technology as CFO. That follows CEO Shantanu Narayen's March announcement that he will step down after 18 years once a successor is named. Steve Day has been named interim CFO. The company is without a permanent CEO.
A double leadership vacuum on an earnings day is enough to create selling pressure. But the leadership risk alone doesn't explain a 50% drawdown. The market is pricing something more structural: the fear that Firefly's generative AI capabilities are moving from a differentiator to a commodity - a feature that's becoming table stakes rather than a moat.
Wall Street has flagged concerns about Adobe pushing toward "freemium" AI services. The concern isn't that AI doesn't work for creative professionals - it's that the monetization model is unclear. When the generative AI content creation market is projected to grow from $11 billion in 2023 to $175 billion by 2033, the question becomes who captures that value and how. Adobe built the distribution - Creative Cloud now has an estimated 41 million paid subscribers - but the architecture of AI-generated content creation could flatten the premium that subscription software has carried for a decade.
I believe this is what separates Adobe's situation from a typical earnings-related selloff. The market isn't rejecting Adobe's execution. It's rejecting the old framework for valuing creative software when AI makes the output easier to produce. If Firefly becomes the table-stakes feature that every competitor offers - and the cost of generating AI content drops toward zero - the subscription premium that Adobe has built its valuation on starts to look fragile.
That said, Firefly first-time subscriptions doubled this year, and AI is acting as a retention tool and upsell driver. The product is working. The question is whether it's working enough to justify a $400 stock when the same AI capabilities are being offered for free or near-free by competitors. I lean toward the view that Adobe's moat is narrower than investors believed at the peak - but not absent. The Creative Cloud installed base, the enterprise workflows, the document AI capabilities, and the DAM (digital asset management) integration create real switching costs. Those matter more than anyone is giving credit for at $196.
Chewy and Boston Scientific: Guidance is the only metric that survives
Chewy and Boston Scientific aren't AI plays, and they don't need to be to illustrate the point that the market has shifted entirely to forward-looking pricing.
Chewy's Q1 revenue of $3.36 billion grew 7.7% year over year, with 21.5 million active customers - up 3.6%. EPS of $0.43 beat forecasts by nearly 80%. Gross margin held at 30.1%. This is a company executing on its core business. But management cut the FY26 sales outlook to $13.40–13.55 billion, down from the prior forecast of $13.6 billion, citing softer consumer spending and weaker premiumization in pet products.
CEO Sumit Singh flagged that households are feeling "more stretched". Put plainly: pet owners are trading down. When the consumer that was supposed to be immune to economic pressure - the person who spends on their dog - is showing softness, Chewy's growth assumption changes. The company is pivoting toward clinics, health services, and AI to diversify, but that's a multi-year build. The near-term reality is that the premium pet food basket is shrinking.
Boston Scientific's case is structurally different. The company didn't miss on Q1 - it topped estimates. But management walked organic growth guidance down in a series of cuts that tell a story of compounding headwinds. The standalone WATCHMAN business - a left atrial appendage closure device for stroke prevention - went from being a growth engine to flat dollar growth. Cardiac electrophysiology, once the fastest-growing segment, is facing intensified competition. Full-year organic growth guidance settled at 6.5–8%, down from the 15.8% the company delivered in the prior year.
The CEO called the guidance cuts disappointing. The market called it a 57% stock decline - from $109.50 to the $45.99 low in mid-June.
Where the capital goes
The debate isn't whether these companies are still functional businesses. Adobe is printing record revenue. Chewy is growing. Boston Scientific is still a leading medtech operator with real product pipelines.
The debate is about the return profile and what the market is demanding to see before it trusts forward guidance again.
For Adobe, I'm watching one thing: whether Firefly's AI monetization shows up as incremental revenue or just as a retention tool that prevents churn. If it's the latter, the stock has priced in a downgrade of the AI thesis that may go too far. If it's the former, the 50% drawdown is buying the AI-creative-software transition at a discount. The leadership vacuum is a real risk - but at these levels, a new CEO with a clear AI monetization roadmap could flip the narrative quickly. I believe Adobe is a candidate for a small allocation at the 52-week low, not a large position. The architecture hasn't broken, but the market needs proof that AI revenue is additive, not just defensive.
For Chewy and Boston Scientific, the thesis is different - and neither belongs in an AI-focused portfolio. Chewy's consumer weakness is a macro signal that matters more as a bellwether than as a standalone trade. Boston Scientific's medtech slowdown is product-cycle specific and deserves a medtech specialist's lens, not mine.
What these three stocks share is a reminder I keep coming back to: the market is no longer rewarding backward execution. It's punishing forward uncertainty. In an AI world where the next product generation can rewrite a business model in 18 months, the quarter that just ended matters less than the architecture that will dominate the next one.
That's why Adobe deserves the most attention here. It's the company where the AI transition is the actual story - not the supply chain signal, not the consumer spend data, but the question of whether creative software can still carry a premium when AI makes the output itself commoditized. The stock has already priced a "no" answer. The question is whether the market is right.
What would change my view: If Adobe's next earnings call shows Firefly generating substantial incremental subscription revenue - not just retention - and a permanent CEO is named with a concrete AI monetization roadmap, the risk/reward flips back toward the bull side. If, instead, management continues to frame AI as a defensive moat and leadership uncertainty stretches beyond Q3, the market's "no" answer may be correct for longer than most bulls want to hold.
The debate is not whether Adobe stays important. It is whether the return profile at $196 - in a stock that was $405 a year ago - is still as compelling as what can be found elsewhere in the AI trade where execution risk is lower and the architecture is already proven.